Inovio Pharmaceuticals (INO) – Research Analysts’ Weekly Ratings Updates

Inovio Pharmaceuticals (NASDAQ: INO) recently received a number of ratings updates from brokerages and research firms:

  • 1/12/2018 – Inovio Pharmaceuticals was given a new $13.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 1/9/2018 – Inovio Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Inovio’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging. We are also positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s targeted cervical cancer market holds untapped potential. On the flip side, as the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Shares of the company have underperformed the industry in the last one year.”
  • 1/3/2018 – Inovio Pharmaceuticals was given a new $13.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 1/2/2018 – Inovio Pharmaceuticals was given a new $12.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock. They wrote, “Inovio announced an amended agreement with ApolloBio (NEEQ: 430187) to develop and commercialize VGX-3100 for precancerous HPV (human papillomavirus) infections and dysplasias (cervical, vulvar, anal) in Greater China (China, Hong Kong, Macao, Taiwan, potentially Korea too). Inovio will receive an upfront payment of $23M plus milestones and royalties. The deal is expected to close in 1Q18.””
  • 11/28/2017 – Inovio Pharmaceuticals was given a new $13.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 11/13/2017 – Inovio Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Inovio reported wider-than-expected loss in the third quarter of 2017 with revenue missing estimates. As the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Meanwhile highly lucrative immuno-oncology market has been the focus area of several big pharma giants which may pose intense competition to the candidates once approved. Shares of the company have underperformed the industry so far this year. However, we are positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging.”

Inovio Pharmaceuticals Inc (NASDAQ INO) traded down $0.01 during trading hours on Friday, reaching $4.46. The company’s stock had a trading volume of 740,946 shares, compared to its average volume of 1,300,000. Inovio Pharmaceuticals Inc has a 1 year low of $4.09 and a 1 year high of $9.86. The firm has a market capitalization of $404.53, a price-to-earnings ratio of -3.78 and a beta of 2.74.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. The company had revenue of $2.60 million during the quarter, compared to analyst estimates of $10.27 million. During the same period in the previous year, the company posted ($0.28) EPS. The company’s quarterly revenue was down 79.2% compared to the same quarter last year. sell-side analysts expect that Inovio Pharmaceuticals Inc will post -1.12 earnings per share for the current fiscal year.

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Receive News & Ratings for Inovio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Anticipate Merrimack Pharmaceuticals Inc  Will Announce Earnings of -$0.28 Per Share
Brokerages Anticipate Merrimack Pharmaceuticals Inc Will Announce Earnings of -$0.28 Per Share
Stephens Analysts Give Heico  a $84.00 Price Target
Stephens Analysts Give Heico a $84.00 Price Target
Dignity’s  Hold Rating Reaffirmed at Peel Hunt
Dignity’s Hold Rating Reaffirmed at Peel Hunt
Zacks Investment Research Lowers Cognizant Technology Solutions  to Hold
Zacks Investment Research Lowers Cognizant Technology Solutions to Hold
Insider Selling: American Public Education, Inc.  Director Sells 400 Shares of Stock
Insider Selling: American Public Education, Inc. Director Sells 400 Shares of Stock
AllianzGI Convertible & Income 2024 Target Term Fund of Beneficial Interest  Insider Justin Kass Purchases 1,500 Shares
AllianzGI Convertible & Income 2024 Target Term Fund of Beneficial Interest Insider Justin Kass Purchases 1,500 Shares


Leave a Reply

 
© 2006-2018 Zolmax.